Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with
patients having a poor prognosis. Approximately one third of NSCLC patients present with …

Surgery is regarded as the primary treatment modality for early stage non-small cell lung
cancer (NSCLC), but even after complete resection, a substantial percentage of these …

Despite surgical resection, patients with early-stage (I to IIIA) non–small cell lung cancer
(NSCLC) are at considerable risk of recurrence and death from their lung cancer. In recent …

Less than 20–25% of non-small cell lung cancer (NSCLC) patients present with stage I or II
disease are best treated by surgical resection. Long-term survival in NSCLC remains poor …

Surgery alone has long been the standard treatment for patients with operable non–small-
cell lung cancer (NSCLC). However, despite complete resection, 5-year survival rates have …

The past decade has witnessed renewed interest in studies exploring the benefits of
adjuvant (postoperative) chemotherapy (±radiation therapy) in patients with resected non …

Radical surgery remains the only treatment with curative potential for patients with operable
non-small cell lung cancer (NSCLC). However, despite complete surgical resection, long …

Patients with clinical stage I and II non-small cell lung cancer (NSCLC) generally are
considered candidates for surgical resection, with cure rates as high as 80% reported for …

Following the 1995 meta-analysis on the role of postoperative chemotherapy in NSCLC,
many randomized controlled trials (RCTs) have evaluated the effect of adjuvant cisplatin …

Objective: Although surgical resection alone is considered adequate treatment in stage IB
non-small-cell lung cancer (NSCLC), long-term survival is not satisfactory and the …